



THE LONDON SCHOOL
OF ECONOMICS AND
POLITICAL SCIENCE ■

Allocation rules for global donors

LSE Research Online URL for this paper: <http://eprints.lse.ac.uk/101210/>

Version: Accepted Version

Article:

Morton, Alec, Arulsevan, Ashwin and Thomas, Ranjeeta (2018) Allocation rules for global donors. *Journal of Health Economics*, 58. pp. 67-75. ISSN 0167-6296

<https://doi.org/10.1016/j.jhealeco.2018.02.003>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Allocation rules for global donors

Alec Morton*, Ashwin Arulsevan† Ranjeeta Thomas‡

February 1, 2018

Abstract

In recent years, donors such as the Bill and Melinda Gates Foundation, have made an enormous contribution to the reduction of the global burden of disease. It has been argued that such donors should prioritise interventions based on their cost-effectiveness, that is to say, the ratio of costs to benefits. Against this, we argue that the donor should fund *not* the most cost-effective interventions, but rather interventions which are just cost-ineffective for the country, thus encouraging the country to contribute its own domestic resources to the fight against disease. We demonstrate that our proposed algorithm can be justified within the context of a model of the problem as a leader-follower game, in which a donor chooses to subsidise interventions which are implemented by a country. We argue that the decision rule we propose provides a basis for the allocation of aid money which is efficient, fair and sustainable.

1 Introduction

The last fifteen years have seen huge strides forward in humanity's ability to protect itself against disease. According to the United Nations (2015), improved prevention and treatment has saved around 37 million lives over this period and 6.2 million lives from malaria (most of the latter being those of children). 13.6 million people living with HIV are now on antiretroviral therapy: many of these people would be dead without treatment.

Although some of this progress is due to economic growth and technological progress, a considerable share is due to aid money from rich countries and philanthropic individuals. In particular, the Global Fund to Fight Aids Tuberculosis and Malaria has disbursed \$27 billion to low and middle income countries to assist them in funding treatments for these three diseases since its founding in 2002 (The Global Fund, n.d.).

*Strathclyde Business School, University of Strathclyde. Corresponding author - email: alec.morton@strath.ac.uk; postal address: Room 720, Sir William Duncan Wing, University of Strathclyde Business School, 199 Cathedral Street, GLASGOW, Scotland, G4 0QU, United Kingdom

†Strathclyde Business School, University of Strathclyde.

‡School of Public Health, Faculty of Medicine, Imperial College London.

Of course, funding is not unlimited. Many rich countries are preoccupied with their own problems: slow growth, ageing populations, the hangover of the financial crisis, the threat of terrorism and the like. In this environment, overseas development aid can be a tough sell to a sceptical public. Private individuals are not constrained in the same way, but even the largest private fortunes are finite. This is reflected in the trends in development assistance for health (DAH). Between the 2000 and 2009 DAH rose at an annualised growth rate of 11.3% with an average annual increase of \$290.4 mn (2015 US\$) in the millennium development goals (MDG) focus areas and \$98.6 mn (2015 US\$) in the non-MDG focus areas. Between 2010 and 2015 however, the annualised growth rate fell to 1.2%, with DAH for HIV/AIDS and other focus areas (with the exception of maternal and newborn/child health) remaining flat or decreasing (Dielman et al 2016).

How, then, should aid money be spent? Several commentators have advocated the use of cost-effectiveness analysis (Center for Global Development, 2013; Teerawattananon et al, 2013). In its simplest form, cost-effectiveness analysis involves prioritising investments in decreasing order of benefit to cost ratio, that is to say “value for money”. In health economics in particular, the benefits are normally operationalised as some sort of health benefit: for example infections averted or life years or quality adjusted life years (QALYs) gained (for more comprehensive expositions, see Tan-Torres Edejer et al, 2003, Drummond et al, 2015; Neumann et al, 2016 and Wilkinson et al., 2016). While assessing these cost-effectiveness ratios for a given set of healthcare interventions can involve substantial clinical and epidemiological expertise, the underlying cost-effectiveness principle is familiar and intuitive.

In this note we take issue with the argument that donors should fund the most cost-effective interventions, with cost-effectiveness defined as total cost of implementation per unit of benefit, at least when the partner countries are middle-income or at the upper end of the lower-income scale. We maintain that a disadvantage of such rules is that they result in the crowding out of indigenous financing of interventions, and thus result in under-allocation of resources to healthcare. We propose an alternative rule for such countries whereby donors subsidise interventions which are “at the margin” from the point of view of the recipient country, that is to say in interventions which are only just cost-ineffective for that country.

To our knowledge this is the first analytic study of this issue, and accordingly there is little relevant literature to review. There is an empirical literature on the so-called “fungibility” of aid (e.g. Lu et al, 2010; Roodman, 2012; Van de Sijpe, 2013; Dykstra et al, 2015) but this is more concerned with empirical estimation of the extent to which external money displaces local financing. There is a classic technical literature on game theoretic analysis of the relationships between different players in the aid system (e.g. Svensson, 2000; Martens et al, 2002), but this differs from our study, which is much more operationally focussed on the derivation of decision rules for one party - the donor - in this relationship.

Our study can be seen as falling in a tradition of studies which seek to

generalise the rules of cost-effectiveness analysis by showing how these rules can be derived within a formal optimisation model (e.g. Weinstein and Zeckhauser, 1973; Morton, 2014, van Baal et al., 2016; Morton et al, 2016; van Baal et al, 2018). The optimisation framework we use here is bilevel programming, which has to our knowledge not hitherto been used in this context: specifically the model which we use can be considered as a bilevel knapsack model. There are quite a few bilevel knapsack models that are present in the operations research literature (Caprara et al., 2013). Most of them cannot be applied to model our application as these models involve the leader and the follower competing for a common resource or the follower is pessimistic with a conflicting objective. Dempe and Richter’s (2000) model is perhaps the closest to the one that we are proposing. However, their model involves in the leader just determining the capacity of the follower’s knapsack and it does not offer the flexibility in terms of individual project subsidies.

The overall structure of the paper is as follows. In Section 2 we present the intuition behind our rule and demonstrate it with respect to a realistic numerical example. In Section 3, to make our argument precise, we provide a formal model of the problem of donor aid allocation as a leader-follower (Stackelberg) game and show that our Section 2 algorithm can be understood as a heuristic version of the optimal solution to this game. In Section 4, we discuss the prospects for using the model we propose to guide resource allocation to countries. Section 5 concludes.

2 Concept and example

A popular approach to prioritisation in healthcare is to evaluate possible healthcare interventions (henceforth “projects”) on the basis of their incremental cost-effectiveness ratio (ICER). This ICER is the ratio of the incremental costs to the incremental benefits relative to the current standard of care, with the latter measured in a metric such as QALYs. A common prescription is to invest only in those projects which meet some cost-effectiveness threshold. This idea has the merit of being both grounded in economic theory and also practically implementable: it informs decision making in many countries.

Suppose a donor (henceforth “D”) wishes to interact with a country (“C”) which makes decisions on this basis. How should D make decisions? What we propose in this paper is that D rather than selecting cost-effective projects on C’s behalf, D should frame its role as deciding which projects to subsidise in order to make them cost-effective for C.

The intuition behind our proposed approach can be depicted visually in Figure 1. In this figure the diagonal represents the line of marginal cost-effectiveness. The green squares above the diagonal represent the low CER projects which will be implemented by C (before subsidy) and the red circles below the diagonal represent high CER projects which will be rejected by C before subsidy. The decision of the donor is thus to choose which (red) projects to subsidise so that they are brought onto the diagonal line.




Figure 1: Intuition behind the Donor's allocation rule

This suggests an approach to prioritisation whereby D calculates its own Subsidy Effectiveness Ratio (SER) for projects by using the required subsidy, rather than the full cost of the project, as the numerator in the SER.

We demonstrate the approach numerically with the following example, based on earlier consultancy work. Consider a middle-income country which faces a range of projects in the areas of TB, malaria and HIV treatment and prevention, with costs and benefits (the latter measured in DALYs) and ICER as shown in Table 1. These projects may be considered to be targeted at separate populations and so are independent.

The first step is to order the projects in order of ICERs and identify those which have an ICER less than C's threshold, which we consider for the purposes of this example to be \$100 per DALY averted. These projects are shown in Table 2.

For the remaining projects, we now perform some additional calculations, shown in Table 3. The raw data for our calculations are the costs and benefits scores (columns 1 and 2) which we denote as c and b . To make the projects cost-effective for a country with a \$100 per DALY threshold, D will have to subsidise these projects by paying an amount δ equal to the ICER (column 3) of the project minus 100, all multiplied by the DALY benefits of the project (column 4) ($b(c/b - 100)$). The balance of funds required to implement each project is

Table 1: Cost and benefit data for HIV, Malaria and TB projects

Disease - Intervention	Costs (\$)	Benefits (DALYs)	ICER
HIV - ART -Firstline	128,222,171	227,193	564.38
HIV - Blood safety	15,037,684	181,862	82.69
HIV - Condom provision	8,569,559	278,120	30.81
HIV - Condom Social Marketing	7,154,969	1,102,885	6.49
HIV - IDU community outreach and peer education	13,078,729	350,754	37.29
HIV - IDU needle and syringe exchange	13,904,682	372,905	37.29
HIV - Mass media	290,738	77,530	3.75
HIV - MSM	57,778,601	8,906,143	6.49
HIV - PMTCT	3,976,386	37,158	107.01
HIV - PMTCT Screening	45,655,271	954,382	47.84
HIV - Safe injection	10,597,302	46,075	230.00
HIV - School based education programs	4,319,850	39,178	110.26
HIV - STI management	184,701,755	7,121,032	25.94
HIV - VCT	30,774,512	643,314	47.84
HIV - Workplace	276,476	4,211	65.66
HIV - Youth focused interventions	80,232	1,222	65.66
Total HIV	524,418,917	20,343,962	
Malaria - ACT - adults public+none (testing and treatment)	79,638	4,580	17.39
Malaria - ACT - children (testing and treatment)	773	44	17.39
Malaria - IRS households	116,207,217	607,461	191.30
Malaria - LLIN	82,765,362	2,291,876	36.11
Total Malaria	199,052,990	2,903,961	
TB - DOTS	227,708,000	1,370,084	166.20
TB - MDR-TB	75,874,050	116,290	652.46
TB - Standard Diagnostic Test	15,049,840	95,290	157.94
Total TB	318,631,890	1,581,664	
Grand total	1,042,103,797	24,829,587	

met by C ($c - \delta$) and is shown in (column 5), which finds the subsidised projects (marginally) cost-effective. The donor then calculates a Subsidy Effectiveness Ratio (SER, δ/b) by comparing the benefits to be realised with this required subsidy (column 6). If for example, D has \$153m, it may choose to implement the projects shown in bold on the table, which are identified by lining projects up in cost-effectiveness order and implementing projects successively in order of SER. We can verify (column 7) that this does indeed exhaust the budget.

Table 2: Projects which are already cost-effective given the country's threshold

Disease - Intervention	Costs (\$)	Benefits (DALYs)	Country ICER
HIV - Blood safety	15,037,684	181,862	82.69
HIV - Youth focused interventions	80,232	1,222	65.66
HIV - Workplace	276,476	4,211	65.66
HIV - VCT	30,774,512	643,314	47.84
HIV - PMTCT Screening	45,655,271	954,382	47.84
HIV - IDU community outreach and peer education	13,078,729	350,754	37.29
HIV - IDU needle and syringe exchange	13,904,682	372,905	37.29
Malaria - LLIN	82,765,362	2,291,876	36.11
HIV - Condom provision	8,569,559	278,120	30.81
HIV - STI management	184,701,755	7,121,032	25.94
Malaria - ACT - children (testing and treatment)	773	44	17.39
Malaria - ACT - adults public+none (testing and treatment)	79,638	4,580	17.39
HIV - Condom Social Marketing	7,154,969	1,102,885	6.49
HIV - MSM	57,778,601	8,906,143	6.49
HIV - Mass media	290,738	77,530	3.75
Total	460,148,981	22,290,858	

Table 3: Worked example showing pattern of funding and subsidies of projects

Disease - Intervention	1. Costs, c	2. Benefits, b	3. Country ICER, c/b	4. Donor Subsidy, $\delta = b(c/b - 100)$	5. Country contribution, $c - \delta$	6. Donor SER, δ/b	7. Cumulative cost to Donor
TB - MDR-TB	75,874,050	116,290	652.46	64,245,063	11,628,987	552.46	328,081,913
HIV - ART	128,222,171	227,193	564.38	105,502,849	22,719,322	464.38	263,836,850
HIV - Safe injection	10,597,302	46,075	230.00	5,989,780	4,607,523	130.00	158,334,001
Malaria - IRS households	116,207,217	607,461	191.30	55,461,155	60,746,062	91.30	152,344,221
TB - DOTS	227,708,000	1,370,084	166.20	90,699,576	137,008,424	66.20	96,883,066
TB - Standard Diagnostic Test	15,049,840	95,290	157.94	5,520,855	9,528,985	57.94	6,183,490
HIV - School based education programs	4,319,850	39,178	110.26	402,063	3,917,787	10.26	662,634
HIV - PMTCT	3,976,386	37,158	107.01	260,572	3,715,815	7.01	260,572
Total for bold projects	367,261,292	2,149,170		152,344,220	214,917,071		

∞

In this example C spends approximately \$460m on interventions which are already cost-effective for it, before D's financing begins to kick in. Had D spent money on these cost-effective interventions, it may well have crowded out financing from C. Instead, D's additional financing leverages substantial amounts of additional funding (\$215m) into the healthcare system over and above what the country would have spent if left to its own devices. Thus, D's financing should be seen in the context of, and indeed as a stimulus to, sustainable financing of the whole system.

Now consider the case where C and D do not agree on the assessment of the benefits of the projects. There are many reasons why this might be so: for example, D may wish to give priority involving children, but C may wish to prioritise working age adults: or D may calculate gains in terms of DALYs and C in terms of productivity losses). We consider a the case where C has a preference for treating some diseases over others (perhaps because it deprioritises diseases which affect politically marginal and social stigmatised populations). Specifically we consider that while D's assessment of the benefits remains as per Table 1, C takes the view that the HIV interventions only realise thirty percent of the benefits of Table 1 across the board. The country's new priority ordering and funded projects are as shown in Table 4.

Because of C's reassessment of the benefits, *HIV-condom provision* (for example) is no longer cost-effective for it. D calculates how much it will have to pay in order to induce C to introduce the other projects and calculates its own cost-effectiveness ratio for the projects which remain unfunded, as shown in Table 5. The calculations are similar to the those of Table 3, differing only in that now instead of there being a single agreed benefit b , there is C's valuation of the benefits v , and D's valuation of the benefit w – for the formulae see the column headings of the table. (Observe that the orderings by country ICER and donor SER respectively, are no longer the same). Again D has \$153m to invest, and the top cost-effective projects on which to spend this money are again shown in bold. This time, from its point of view, the most cost-effective projects to subsidise are the HIV projects which C has left on the table. Because it uses its budget subsidising such projects, it no longer has enough money to fund the *Malaria –IRS households* project.

Table 4: Priorities for C with reduced benefits from HIV projects

Disease - Intervention	Costs	Country's valuation of Benefits	Donor's valuation of Benefits	Country ICER
HIV - ART -Firstline	128,222,171	68,158	227,193	1881.25
HIV - Safe injection	10,597,302	13,823	46,075	766.67
TB - MDR-TB	75,874,050	116,290	116,290	652.46
HIV - School based education programs	4,319,850	11,753	39,178	367.54
HIV - PMTCT	3,976,386	11,147	37,158	356.71
HIV - Blood safety	15,037,684	54,558	181,862	275.63
HIV - Youth focused interventions	80,232	367	1,222	218.88
HIV - Workplace	276,476	1,263	4,211	218.88
Malaria - IRS households	116,207,217	607,461	607,461	191.30
TB - DOTS	227,708,000	1,370,084	1,370,084	166.20
HIV - PMTCT Screening	45,655,271	286,315	954,382	159.46
HIV - VCT	30,774,512	192,994	643,314	159.46
TB - Standard Diagnostic Test	15,049,840	95,290	95,290	157.94
HIV - IDU community outreach and peer education	13,078,729	105,226	350,754	124.29
HIV - IDU needle and syringe exchange	13,904,682	111,871	372,905	124.29
HIV - Condom provision	8,569,559	83,436	278,120	102.71
<i>HIV - STI management</i>	<i>184,701,755</i>	<i>2,136,309</i>	<i>7,121,032</i>	<i>86.46</i>
<i>Malaria - LLIN</i>	<i>82,765,362</i>	<i>2,291,876</i>	<i>2,291,876</i>	<i>36.11</i>
<i>HIV - Condom Social Marketing</i>	<i>7,154,969</i>	<i>330,866</i>	<i>1,102,885</i>	<i>21.63</i>
<i>HIV - MSM</i>	<i>57,778,601</i>	<i>2,671,843</i>	<i>8,906,143</i>	<i>21.63</i>
<i>Malaria - ACT - children (testing and treatment)</i>	<i>773</i>	<i>44</i>	<i>44</i>	<i>17.39</i>
<i>Malaria - ACT - adults public+none (testing and treatment)</i>	<i>79,638</i>	<i>4,580</i>	<i>4,580</i>	<i>17.39</i>
<i>HIV - Mass media</i>	<i>290,738</i>	<i>23,259</i>	<i>77,530</i>	<i>12.50</i>

Table 5: Priorities for C with reduced benefits from HIV projects

Disease - Intervention	1. Costs, c	2. Country's valuation of Benefits, v	3. Country ICER, c/v	4. Subsidy required make cost-effective, $\delta = v(c/v - 100)$	5. Donor's valuation of Benefits, w	6. Donor SER, δ/w	7. Cumulative cost to Donor
TB - MDR-TB	75,874,050	116,290	652.46	64,245,063	116,290	552.46	396,328,330
HIV - ART -Firstline	128,222,171	68,158	1881.25	121,406,374	227,193	534.38	332,083,266
HIV - Safe injection	10,597,302	13,823	766.67	9,215,046	46,075	200.00	210,676,892
Malaria - IRS households	116,207,217	607,461	191.30	55,461,155	607,461	91.30	201,461,846
HIV - School based education programs	4,319,850	11,753	367.54	3,144,514	39,178	80.26	146,000,692
HIV - PMTCT	3,976,386	11,147	356.71	2,861,642	37,158	77.01	142,856,178
TB - DOTS	227,708,000	1,370,084	166.20	90,699,576	1,370,084	66.20	139,994,536
TB - Standard Diagnostic Test	15,049,840	95,290	157.94	5,520,855	95,290	57.94	49,294,960
HIV - Blood safety	15,037,684	54,558	275.63	9,581,835	181,862	52.69	43,774,104
HIV - Youth focused interventions	80,232	367	218.88	43,575	1,222	35.66	34,192,270
HIV - Workplace	276,476	1,263	218.88	150,159	4,211	35.66	34,148,694
HIV - PMTCT Screening	45,655,271	286,315	159.46	17,023,797	954,382	17.84	33,998,535
HIV - VCT	30,774,512	192,994	159.46	11,475,105	643,314	17.84	16,974,738
HIV - IDU community outreach and peer education	13,078,729	105,226	124.29	2,556,118	350,754	7.29	5,499,633
HIV - IDU needle and syringe exchange	13,904,682	111,871	124.29	2,717,543	372,905	7.29	2,943,515
HIV - Condom provision	8,569,559	83,436	102.71	225,972	278,120	0.81	225,972

D might take the view that if C assesses projects very differently from D, D may require that C apply a higher cost-effectiveness threshold for its own projects as a condition of funding. For example, if C chooses to put a lower value on projects aimed at sex workers or sexual minorities in its own internal valuation, it does not seem right that D should pick up such projects without demanding that C provide some additional funding for some other projects (otherwise C would financially benefit from its reluctance to provide to health services to all of its citizens on an equitable basis).

We run some scenarios on our base model which we present in Figure 2 to show how the relative sums of money allocated by C and D respectively change as we redo the calculations varying C’s threshold. As can be seen from the figure, as C’s threshold is stepped up, the amount of financing that the C contributes in the model increases – this is partly because increasing the threshold tips some projects over from being subsidised to being entirely funded by C but also because the amount of subsidy that C receives for any subsidised project diminishes, as it requires less financial support to make it cost-effective. D’s contribution fluctuates because D has a budget constraint which it cannot exceed, but sometimes it chooses not to use its full budget (for example if it only has half the amount necessary to make a project cost-effective, it does not make sense to subsidise the project by that amount as this will not be sufficient to change C’s decision).

What lessons might D draw from this graph? Observe that before discounting the benefits of its HIV projects, C would spend \$675m of its own money on healthcare, comprising \$460m from the unsubsidised projects (see Table 2) and \$215m for its share of the subsidised projects (see Table 3). After discounting its HIV projects, it is possible to work out from the data of Tables 4 and 5 that C would reduce its spending down to \$565m. If D wishes to raise country funding back to \$675m, they can identify the threshold λ^* which corresponds to C spending \$675m into the system even with the discounted HIV projects. They may then wish to bargain with C to apply a threshold of λ^* (which in this case = \$117) rather than \$100 per DALY averted as a condition of funding.

3 Model

In this Section, we provide some formal context to the procedure of the previous Section. We model the interaction between a donor D and country C as a Stackelberg (or leader-follower) game. D is the leader and makes a decision about how much to subsidise healthcare programmes; C decides what healthcare programmes to implement based on the schedule of subsidies on offer, but also how much to invest in healthcare relative to what we call their “outside option” - an alternative investment opportunity which is not valued by D. One can think of the outside option as being the *opportunity cost* of expenditure on healthcare.

Our model is as follows. We first consider the problem of the donor, D:




Figure 2: Payments by donor and country as the threshold is varied

$$\begin{aligned}
& \max \quad \sum_{i \in I} w_i x_i \\
& \text{s.t.} \quad \sum_{i \in I} \delta_i \leq B_{donor} && (DONOR) \\
& \quad \delta_i \geq 0 && \forall i \in I \\
& \quad x \in \text{argmax}(COUNTRY)
\end{aligned}$$

- $I = 1, \dots, i, \dots, n$ is the index set of a set of healthcare projects
- w_i is the (positive) value of healthcare project i to D
- x_i are decision variables indicating whether healthcare project i is funded or not, and the vector of these decision variables is denoted x
- δ_i are decision variables indicating the level of subsidy provided by D to healthcare project i
- B_{donor} is D's budget constraint

We comment in particular on the constraint that $x \in \text{argmax}(COUNTRY)$. This is the element of the formulation which makes this a bilevel programme. The constraint says that the x vector is constrained to be a solution of another optimisation problem (the “inner problem”, here called *COUNTRY*). Procedures to solve such problems are generally highly dependent on the structure of the inner problem, and are typically not computationally straightforward.

In other words, a critical element of D's problem is that she does not actually allocate the funding, she merely decides on a set of subsidies which are used by C in solving *COUNTRY*. In this sense D can be thought of as a funding agency (such as the Global Fund) which provides financing to country partners and audits results, rather than an implementation agency, such as President's Malaria Initiative, which actually runs and manages programmes on the ground, in-country itself.

C's problem is as follows:

$$\begin{aligned}
 \max \quad & \sum_{i \in I} v_i x_i + V_0 x_0 \\
 \text{s.t.} \quad & \sum_{i \in I} (c_i - \delta_i) x_i + C_0 x_0 = B_{country} && (\text{COUNTRY}) \\
 & x_i \in \{0, 1\} && \forall i \in I \\
 & x_0 \in [0, 1]
 \end{aligned}$$

The intended interpretation of this model is as follows:

- v_i is the (positive) value of healthcare project i to C and V_0 is the value of the outside option
- c_i is the (positive) cost of healthcare project i to C and C_0 is the cost of the outside option
- $B_{country}$ is C's budget constraint
- x_0 is a decision variable indicating the extent to which the outside option is funded

One possibly contentious feature of this model is the linearity of the outside option. This assumption can be considered as justified by a sort of Taylor-series assumption - there are many opportunities for government investment in the public sector outside health, and so the local gradient of the production function may be approximately linear. A more pragmatic assumption is that relaxing this assumption of linearity seems to lead to a problem which is more complicated to solve. Another assumption is that the budget constraint is fixed, but it might be that an injection of the donor funds changes the government budget (quite possibly downwards). This assumption we justify as being reasonable when the government budget is relatively large: also it is necessary to advance the analysis.

It may be objected that the value delivered by projects will not scale in a linear way, on the grounds that one would treat the sickest who have greater capacity to benefit first: we reply that this is a modelling rather than a mathematical decision, as in the mathematics there is no minimum size of a "project" - in the extreme case a project could just involve treating one person. We also note that our model assumes that projects can be implemented independently of one another - there are no shared costs or jointly delivered benefits.

We make the following assumption on the parameters of the model:

Assumption 1 $\sum_{i \in I} c_i < B_{country} < C_0$

This assumption can be seen as locating the country as a middle income country in a very direct way: it could fund all healthcare projects currently on the table out of its domestic budget, but this domestic budget is swamped by competing claims from other sectors of government. (The technical reasons for having this assumption will become clear in the course of the proof of Proposition 1.)

Proposition 1 *For every optimal solution to DONOR problem, there exists an optimal solution to the following integer knapsack problem KPD and vice versa.*

$$\begin{aligned} \max \quad & \sum_{i \in I} w_i x_i \\ \text{s.t.} \quad & \sum_{i \in I} \Delta_i x_i \leq B_{donor} \quad (KPD) \\ & x_i \in \{0, 1\}, \forall i \in I \end{aligned}$$

where $\Delta_i = c_i - \frac{v_i C_0}{V_0}$ for all $I_m \subseteq I$ which are defined as the set of marginal projects $\{i : v_i < c_i V_0 / C_0\}$ and $\Delta_i = 0$ for all other projects $i \notin I_m$

Proof. We show this by proving that for an optimal solution to one problem, there exists a feasible solution to the other problem and vice versa.

\Rightarrow Let \mathbf{x}^* , be an optimal solution to *KPD*. First make a quick observation that the optimal solution we consider will have $x_i^* = 1$ for $i \notin I_m$. If not, we can make its value one and we will only to increase the objective value (as $w_i \geq 0$) and we will not violate the budget constraint (as $\Delta_i = 0$). Define $I_m^* := \{i \in I_m : x_i^* = 1\}$ and $\Delta_i^* := \Delta_i x_i^*$, for all $i \in I$. We will first show that the (\mathbf{x}^*, Δ^*) is a feasible solution to *DONOR*. In order to do that we need to first show that there exists a x_0^* , such that (\mathbf{x}^*, x_0^*) is an optimal solution to the *COUNTRY*(Δ^*) (problem *COUNTRY* with the subsidy parameter as Δ^*). We claim that

$$x_0^* = \frac{B_{COUNTRY} - \sum_{i \notin I_m} c_i - \sum_{i \in I_m^*} (c_i - \Delta_i^*)}{c_0}.$$

In order to see this we will take any feasible solution $(\tilde{\mathbf{x}}, \tilde{x}_0)$ to *COUNTRY*(Δ^*) and systematically convert $\tilde{\mathbf{x}}$ into \mathbf{x}^* and show that in this process the objective function only increases. We will now perform the following three operations on $(\tilde{\mathbf{x}}, \tilde{x}_0)$:

- If $\tilde{x}_i = 0$ for some $i \notin I_m$, then we can make $\tilde{x}_i = 1$ and decrease \tilde{x}_0 by $\frac{c_i}{c_0}$ (which we can always do by the first inequality of Assumption 1). Since $\frac{v_i}{c_i} \geq \frac{V_0}{C_0}$, this will only increase the objective function value. Similarly, we can do this for all $i \notin I_m$ with $\tilde{x}_i = 0$.
- Next, for some $i \in I_m / I_m^*$ with $\tilde{x}_i = 1$, we can reduce it to zero and increase \tilde{x}_0 by $\frac{c_i}{c_0}$ (which we can always do by the second inequality of

Assumption 1). Notice that doing this will strictly increase the objective value since $\Delta_i^* = 0$ and $\frac{v_i}{c_i} < \frac{V_0}{C_0}$

- Finally, for some $i \in I_m$ with $\tilde{x}_i = 0$, we can increase it to one and decrease \tilde{x}_i by $\frac{c_i - \Delta_i^*}{C_0}$ (which we can always do by the first inequality of Assumption 1). This will not alter the objective value because $\frac{v_i}{c_i - \Delta_i^*} = \frac{V_0}{C_0}$.

Clearly we have set all $\tilde{x}_i = 0$ for all $i \in I_m/I_m^*$ and $\tilde{x}_i = 1$ for all $i \in I_m^*$ and $i \notin I_m$, which is exactly \mathbf{x}^* . It is also easy to notice that after performing the above operations we get $\tilde{x}_0 = x_0^*$. Therefore $\mathbf{x}^* \in \text{argmax}(COUNTRY)$, and thus it satisfies the third constraint of *DONOR*. This ends the proof in one direction.

\Leftarrow Let (\mathbf{x}^*, δ^*) be the optimal solution to *DONOR*. We have to show that \mathbf{x}^* is a feasible solution to *KPD*. We will only focus on $i \in I_m$ with $x_i^* = 1$. Any other project, i , will not affect the feasibility of *KPD*, since we either have $\Delta_i = 0$ (when $i \notin I_m$) or we have $x_i^* = 0$. For some $i \in I_m$ with $x_i^* = 1$, we should notice that $\delta_i^* \geq c_i - \frac{v_i C_0}{V_0}$. Let us assume the contrary: $\delta_i^* < c_i - \frac{v_i C_0}{V_0}$. If we reduce the value of x_i^* to 0 and increase the value of x_0^* by $\frac{c_i - \delta_i^*}{C_0}$, then the objective value of *COUNTRY*(δ^*) would strictly increase by a value of $V_0 \frac{c_i - \delta_i^*}{C_0} - v_i$, because $V_0 \frac{c_i - \delta_i^*}{C_0} - v_i > 0$ by assumption. This is a contradiction to the optimality of (\mathbf{x}^*, x_0^*) to *COUNTRY*(δ^*). So we indeed have $\delta_i^* \geq c_i - \frac{v_i C_0}{V_0}$. But from the feasibility of (\mathbf{x}^*, δ^*) to *DONOR*, we have

$$\sum_{i \in I} \delta_i^* \leq B_{DONOR}$$

From the above claim we just proved, we have

$$\sum_{i \in I} \Delta_i x_i^* \leq \sum_{i \in I} \delta_i^*$$

Hence the first constraint of *KPD* is satisfied and this completes the proof.

■

The problem *KPD* is easily solvable using standard software. We find the solutions for the example we introduced in the previous section using the Solver add-in for MSExcel. First we solve the version of the problem in which D and C have the same benefit coefficients. The DALYs gained which can be attributed to projects subsidised by D for the optimal solutions, and the amount of country finance leveraged in thereby, are shown for a range of budget levels in Figures 3A and 3B. It can be seen that the shape of the curves appear similar: in fact they are identical. The reason for this is that each DALY attributable to a project subsidised by D has to be matched by exactly \$100 from C.

Figure 4A and 4B show the corresponding graphs for the example where D and C have different benefit coefficients because C discounts the benefits of the HIV projects. Here the shapes are markedly different. It may be observed

that the curve of Figure 4B looks somehow “more irregular” than that of the other figures, and indeed it is non-monotonic, ie does not always increase as the budget increases. This is because C’s priority ordering is quite different from D’s, so sometimes D may have to put a relatively small amount of money to induce C do to something D regards as relatively attractive, and sometimes a relatively large sum of money to do something D sees as unappealing.

Although it is not difficult to solve the model *KPD* computationally, the model can also be solved heuristically using the approach of Section 2. The approach of Section 2 is not truly optimal: to see this consider the case where D has a budget of \$300,000 and has three investment opportunities: two each involve subsidising \$200,000 and saving 20 lives (at \$100,000 per life saved), and the other involves subsidising \$300,000 and saving 25 lives(at \$120,000 per life saved). Although the \$300,000 subsidy is clearly the least cost-effective of the three, it is also the optimal choice, saving five more lives than either of the other two options, because the fixed budget means that at most one of the three investment opportunities available can be selected. However, although not strictly optimal, the rule of Section 2 has the advantage that it is intuitive and easy to follow rather than going through a “blackbox” algorithm.

4 Discussion

A common criticism of development aid is that it distorts local country priorities and an important principle underlying recent discourse on aid effectiveness is “country ownership”: aid recipients should set and lead their own development strategies, and use aid in pursuing these strategies, rather than having their priorities dictated by outside parties (OECD, 2005/2008). Can the model we have outlined be used in a way which is consistent with this important principle?

In our example and in our model we do not assume that the donor and the country have a common valuation of the healthcare projects which are on the table. (The donor’s vector of benefit coefficients are w and the country’s is v .) There could be many reasons for this. For example, donors and countries may differ in terms of time horizon or in terms of risk attitude. Alternatively, donors may have a mandate only to fund particular diseases, or only diseases of particularly subpopulations (e.g. children), or they may be particularly concerned about global public goods, and so be prepared to support stewardship initiatives which protect against the development of drug resistant pathogens. More fundamentally, donors and countries may have different preferences for the various dimensions of health or even philosophical perspectives on the value of healthcare: for example, countries may justify spending on healthcare on the basis of economic benefits, but donors may prioritise based on reduction of the burden of disease, as measured in Disability Adjusted Life Years (DALYs) or some similar metric.

In short, our model captures a situation in which there is a partnership between parties of overlapping, but not identical, interests and perspectives. This is in our view, an accurate description of the situation in development aid,

and is entirely compatible with country ownership, explicitly acknowledging that the country may have their own objectives which differ from those of the donor.

We believe that acknowledging that such differences exist is essential for an open and respectful dialogue between donor and country about aid which can lead to an arrangement in which there is genuine country ownership. In practice, donors subject country plans to technical evaluation to ensure that the benefits which aid is intended to bring will actually be realised. This is not in itself an infringement of country ownership, as it is intended to help the country realise its own stated objectives.

Our model should not be understood as providing an algorithm for aid allocation but rather a starting point for discussion between donor and country. Given that resources are limited, it is reasonable for donors to initiate discussions by offering to fund expensive treatments for multi-drug resistant tuberculosis, on the basis that countries should fund highly cost-effective interventions (e.g. condom provision for sex workers or men who have sex with men) themselves if they are wealthy enough to do so. In return, if the country can offer some compelling and legitimate argument why this is not feasible in their context, it is incumbent on donors to think again.

An important issue arising from our model and which must be addressed through such a dialogue is the nature of what we have called the “outside option”. Donors, like the Global Fund, may have a mandate which is focussed on particular diseases. This does not mean that they can be blind to the impact of their actions on the rest of the health system, or indeed, the rest of the public sector. Our model provides donors with an allocation rule which encourages countries to invest in health services, if that is their priority. If this encourages countries to implement progressive taxation or crack down on corruption, or reign in aggressive military expenditure in order to raise funds, this is to be welcomed. If on the other hand, countries respond to these incentives by raiding the education budget, this may not be on balance good for the local population. Such considerations cannot in our view be taken into account by algorithm: there is no substitute for a context-sensitive appraisal of what is happening in country.

An important benefit of the decision rule we suggest is that it (provably, in the context of our model), leverages donor financing by encouraging countries to invest their own money. Moreover, the decision rule suggested by our model is consistent with the recent push for “sustainable” aid. A financial model where the most cost-effective and thus the most basic services of the health system are financed by outside partners is not a sustainable model. As countries move through the development cycle, they must take on responsibility for funding the core of their healthcare system themselves. By choosing judiciously how to allocate their funds, in consultation with countries, donors can add value by topping up health system provision, enabling countries to afford technologies and treatments which would otherwise be beyond their reach.

5 Conclusion

The world has made significant progress in the improving human health over the last several years. However, many people still lack access to the healthcare they need. This is in part because resources are inevitably limited, but also because the resources which are available are often misallocated. Health economics and health economists have a huge potential contribution to make to providing systematic methods to ensure decision makers use these limited resources in the best possible way.

Chalkidou et al (2016) have argued that although the core principles underlying sound and defensible priority setting are the same everywhere, specific solutions have to be tailored to local contexts and problems. The argument of our paper is that this is particularly the case for global donors. Global donors have a responsibility to use funds wisely and this means working in partnership with countries to support countries in developing their own healthcare systems (Kanpirom et al, 2017). The argument of this paper is that the standard algorithm of cost-effectiveness analysis - prioritise in value for money order - is not appropriate where countries do have the wherewithal to share costs. Instead, donors should consider subsidising interventions which are marginal for countries, so as to maximally leverage indigenous country financing. Such a decision rule has the attractive feature that it encourages countries to adopt sustainable financing arrangements, where the most cost-effective components of the healthcare system are funded directly out of core government revenues.

The model we propose is eminently practical as estimates for the key parameters are widely available. For example, the last few years have seen lively discussion of the estimation and role of country-level cost-effectiveness thresholds (Bertram et al, 2016; Woods et al., 2016), which can be thought of as playing the role of the outside option in our model. Although these estimates are not perfect, the more they are seen to play a role in decision making via models like that proposed here, the faster the quality of these estimates will improve. Although we believe it is currently fit for purpose, the model offers scope for development by relaxing assumptions such as project independence, integrality, and certainty about key coefficients. Developing more general models (for example incorporating constraints on non-monetary resources such as staff, incorporating uncertainty on the part of the donor about how the country frames its optimisation problem) is a technically demanding task, and is left as a challenge for future research in this area.

6 References

Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny M-P, Hill SR. Cost-effectiveness thresholds: pros and cons. *Bull World Health Organ* 2016;94: 925-930.

Center for Global Development. More Health for the Money: Putting Incentives to Work for the Global Fund and Its Partners. Center for Global

Development: Washington DC; 2013.

Caprara, A, Carvalho, M, Lodi, A, and Woeginger, GJ. A complexity and approximability study of the bilevel knapsack problem. In Proceedings of the 16th international conference on Integer Programming and Combinatorial Optimization (IPCO'13), Goemans M and Correa J (Eds.). Springer-Verlag: Berlin, Heidelberg, 98-109; 2013.

Chalkidou K, Glassman A, Marten R, Vega J, Teerawattananon Y, Trisavit N, Gyansa-Lutterodt M, Seiter A, Kieny MP, Hofman K, Culyer AJ. Priority-setting for achieving universal health coverage. *Bull World Health Organ* 2016;94; 462-467.

Dempe, S, Richter, K. Bilevel programming with Knapsack constraint. *Central European Journal of Operations Research* 2000; 8; 93-107.

Dielman JL, Schneider MT, Haakenstad A, Singh L, Sadat N, Birger M, Reynolds A, Templin T, Hamavid H, Chapin A, Murray CJ. Development assistance for health: past trends, associations, and the future of international flow for health. *Lancet* 2016; 387(10037);2536-44.

Drummond, MF, Sculpher, MJ, Claxton, K, Stoddart, GL, Torrance, GW. *Methods for the Economic Evaluation of Health Care Programmes*. 4th edition. OUP: Oxford; 2015.

Dykstra, S, Glassman, A, Kenny, C, Sandefur, J. The Impact of Gavi on Vaccination Rates: Regression Discontinuity Evidence. Working Paper 394. Center for Global Development: Washington DC; 2015.

Kanpirom, K, Luz, ACG, Chalkidou, K, Teerawattananon, Y. How Should Global Fund Use Value-for-Money Information to Sustain its Investments in Graduating Countries? *International Journal of Health Policy and Management* 2017; 6(9); 529-533.

Lu C, Schneider MT, Gubbins P, Leach-Kemon K, Jamison D, Murray CJL. Public financing of health in developing countries: a cross-national systematic analysis. *Lancet* 2010;375; 1375-1387.

Martens B, Mummert U, Murrell P and Seabright P. *The Institutional Economics of Foreign Aid*. CUP: Cambridge, 2002.

Morton A. Aversion to health inequalities in healthcare prioritisation: A multicriteria optimisation perspective. *J Health Econ* 2014;36; 164-173.

Morton A, Thomas R, Smith PC. Decision rules for allocation of finances to health systems strengthening. *J Health Econ* 2016; 49; 97-108.

Neumann PJ, Sanders GD, Russel, LB, Siegel, JE and Ganiats, TG. *Cost-effectiveness in health and medicine*. 2nd edition. OUP: Oxford; 2016.

OECD. The Paris Declaration on Aid Effectiveness and the Accra Agenda for Action. OECD: Paris; 2005/ 2008. Available at <http://www.oecd.org/dac/effectiveness/34428351.pdf>. Accessed 27/02/2017.

Roodman D. Doubts about the evidence that foreign aid for health is displaced into non-health uses. *Lancet* 2012;380; 972-973; author reply 973.

Svensson, J. Foreign aid and rent-seeking. *Journal of International Economics* 2000; 51(2).

Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL. 2003. WHO guide to cost-effectiveness analysis. (Eds). World

Health Organisation: Geneva; 2003.

Teerawattananon, Y, McQueston K, Glassman A, Yothasamut J, and Myint CY. Health Technology Assessments as a Mechanism for Increased Value for Money: Recommendations to the Global Fund. *Globalization and Health* 2013; 9(35). doi:10.1186/1744-8603-9-35.

The Global Fund. The Global Fund. <http://www.theglobalfund.org/en/>. n.d. Accessed 25/02/2017.

United Nations. We can end poverty: Millenium Development Goals and Beyond 2015. 2015. <http://www.un.org/millenniumgoals/aids.shtml>. Accessed 25/01/17.

van Baal P, Meltzer D and Brouwer W. Future Costs, Fixed Health Care Budgets and the Decision Rules of Cost Effectiveness Analysis. *Health Econ* 2016; 25(2); 237-248.

van Baal P, Morton A, and Severens J L. Health care input constraints and cost effectiveness analysis decision rules. *Social Science and Medicine* 2018; 200; 59-64.

Van de Sijpe N. The Fungibility of Health Aid Reconsidered. *J Dev Stud* 2013;49; 1746-1754.

Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. *Journal of Public Economics* 1973;2; 147-157.

Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, Teerawattananon Y, Asfaw E, Lopert R, Culyer AJ, Walker DG. The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. *Value Health* 2016;19; 921-928.

Woods B, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. *Value in Health* 2016;19; 929-935.

7 Acknowledgements

This project was stimulated by conversations with the Chief Economist of the Global Fund, Michael Borowitz, and we would like to thank him for his support of this work, and Pete Smith for his wise guidance. We are also grateful to Kalipso Chalkidou, Jeremy Lauer, Yot Teerawattananon and Steve Chick for detailed comments and encouragement. We also wish to thank the audiences at seminars at the Global Fund, the World Health Organization and the Center for Global Development at which this work was presented. We have also benefited from feedback from participants at the Priorities 2016 conference and the IMA and OR Society joint Conference on Mathematics of Operational Research (both in Birmingham), and a workshop at the University of York organised under the International Decision Support Initiative, funded by the Gates Foundation. We would also like to thank seminar participants at seminars in City University of Hong Kong, Singapore University of Technology and Design, the National University of Singapore, Erasmus University Rotterdam, and the Universities of Coimbra, Warwick and Strathclyde, as well as the opportunity to

use this material in a public lecture at Aalto University in Helsinki. Thanks also go to Vikram Pathania, who provided some relevant references in the international development literature. We also express our thanks to Martin Chalkley as handing Editor for this paper and one anonymous referee for their helpful comments.

Ranjeeta Thomas is supported by funding from the HIV Prevention Trials Network 071 Study (HPTN 071). HPTN 071 is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements UM1-AI068619, UM1-AI068617, and UM1-AI068613, with funding from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Additional funding is provided by the International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda Gates Foundation, as well as by NIAID, the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH), all part of NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID, NIMH, NIDA, PEPFAR, 3ie, or the Bill & Melinda Gates Foundation.





Figure 3: Improvements in health and increases in country spending as donor budget scales up (benefit coefficients identical for donor and country)





Figure 4: Improvements in health and increases in country spending as donor budget scales up (benefit coefficients different for donor and country)